Literature DB >> 7287186

Adjuvant activity of carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine on the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs.

I Azuma, H Okumura, I Saiki, M Kiso, A Hasegawa, Y Tanio, Y Yamamura.   

Abstract

The adjuvant activity of 29 kinds of carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine on the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine was examined in guinea pigs. It was found that the D-manno- and D-galacto-type muramyldipeptides were as active as the D-gluco-type muramyldipeptide (MDP). The structural requirement of the carbohydrate moiety of analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine is discussed.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7287186      PMCID： PMC350787          DOI： 10.1128/iai.33.3.834-839.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  16 in total

1.  Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers.

Authors:  A Adam; M Devys; V Souvannavong; P Lefrancier; J Choay; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1976-09-07       Impact factor: 3.575

Review 2.  Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.

Authors:  L Chedid; F Audibert; A G Johnson
Journal:  Prog Allergy       Date:  1978

3.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

4.  Synthesis and immunoadjuvant activities of muramoyl-L-alanyl-D-isoglutamine and some carbohydrate analogs.

Authors:  M Kiso; Y Kaneda; H Okumura; A Hasegawa; I Azuma; Y Yamamura
Journal:  Carbohydr Res       Date:  1980-02       Impact factor: 2.104

5.  Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.

Authors:  I Azuma; K Sugimura; M Yamawaki; M Uemiya; S Kusumoto; S Okada; T Shiba; Y Yamamura
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

6.  Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP).

Authors:  F Audibert; L Chedid; P Lefrancier; J Choay; E Lederer
Journal:  Ann Immunol (Paris)       Date:  1977 Apr-Jun

7.  Adjuvant activity of 6-O-mycoloyl derivatives of N-acetylmuramyl-L-seryl-D-isoglutamine and related compounds in mice and guinea pigs.

Authors:  M Uemiya; K Sugimura; T Kusama; I Saiki; M Yamawaki; I Azuma; Y Yamamura
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

8.  Adjuvant activity of 6-O-mycoloyl-N-acetylmuramuyl-L-alanyl-D-isoglutamine.

Authors:  Y Yamamura; I Azuma; K Sugimura; M Yamawaki; M Uemiya
Journal:  Gan       Date:  1976-12

9.  Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

Authors:  S Kotani; Y Watanabe; F Kinoshita; T Shimono; I Morisaki
Journal:  Biken J       Date:  1975-06

10.  In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice.

Authors:  C Damais; M Parant; L Chedid; P Lefrancier; J Choay
Journal:  Cell Immunol       Date:  1978-01       Impact factor: 4.868
View more
  4 in total

1.  Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.

Authors:  Chikako Ogawa; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  Curr Bioact Compd       Date:  2011-09

Review 2.  Carbohydrate-based immune adjuvants.

Authors:  Nikolai Petrovsky; Peter D Cooper
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

3.  Chemical conjugation of muramyl dipeptide and paclitaxel to explore the combination of immunotherapy and chemotherapy for cancer.

Authors:  Xuqin Li; Junli Yu; Song Xu; Nan Wang; Hongzhen Yang; Zheng Yan; Guifang Cheng; Gang Liu
Journal:  Glycoconj J       Date:  2007-12-27       Impact factor: 2.916

Review 4.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.